Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Lehane

Showing results (111-120 of 121) with videos related to

Pageof 13
Sort By:
Scientific Reports|July 18, 2019
A 4-cyano-3-methylisoquinoline inhibitor of Plasmodium falciparum growth targets the sodium efflux pump PfATP4Paul R Gilson, Rasika Kumarasingha, Jennifer Thompson, et al.
Journal of Medicinal Chemistry|February 22, 2023
Optimization of 2,3-Dihydroquinazolinone-3-carboxamides as Antimalarials Targeting PfATP4Trent D Ashton, Madeline G Dans, Paola Favuzza, et al.
European Journal of Medicinal Chemistry|July 18, 2024
Optimization of pyrazolopyridine 4-carboxamides with potent antimalarial activity for which resistance is associated with the P. falciparum transporter ABCI3Petar P S Calic, Trent D Ashton, Mahta Mansouri, et al.
Chemmedchem|August 30, 2024
Lactam Truncation Yields a Dihydroquinazolinone Scaffold with Potent Antimalarial Activity that Targets PfATP4Trent D Ashton, Petar P S Calic, Madeline G Dans, et al.
ACS Infectious Diseases|November 1, 2016
Biochemical and Structural Characterization of Selective Allosteric Inhibitors of the Plasmodium falciparum Drug Target, Prolyl-tRNA-synthetaseStephen Nakazawa Hewitt, David M Dranow, Benjamin G Horst, et al.
Journal of Medicinal Chemistry|November 8, 2021
An Open Drug Discovery Competition: Experimental Validation of Predictive Models in a Series of Novel AntimalarialsEdwin G Tse, Laksh Aithani, Mark Anderson, et al.
Journal of Medicinal Chemistry|August 12, 2024
Property and Activity Refinement of Dihydroquinazolinone-3-carboxamides as Orally Efficacious Antimalarials that Target PfATP4Trent D Ashton, Petar P S Calic, Madeline G Dans, et al.
Nature Communications|September 30, 2022
A G358S mutation in the Plasmodium falciparum Na<sup>+</sup> pump PfATP4 confers clinically-relevant resistance to cipargaminDeyun Qiu, Jinxin V Pei, James E O Rosling, et al.
Journal of Medicinal Chemistry|April 14, 2025
Optimization and Characterization of N-Acetamide Indoles as Antimalarials That Target PfATP4Jon Kyle Awalt, Zi Kang Ooi, Trent D Ashton, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 3, 2014
(+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of PlasmodiumMaría Belén Jiménez-Díaz, Daniel Ebert, Yandira Salinas, et al.
Pageof 13

Showing results (111-120 of 121) with videos related to

Sort By:
Pageof 13
Scientific Reports|July 18, 2019
A 4-cyano-3-methylisoquinoline inhibitor of Plasmodium falciparum growth targets the sodium efflux pump PfATP4Paul R Gilson, Rasika Kumarasingha, Jennifer Thompson, et al.
Journal of Medicinal Chemistry|February 22, 2023
Optimization of 2,3-Dihydroquinazolinone-3-carboxamides as Antimalarials Targeting PfATP4Trent D Ashton, Madeline G Dans, Paola Favuzza, et al.
European Journal of Medicinal Chemistry|July 18, 2024
Optimization of pyrazolopyridine 4-carboxamides with potent antimalarial activity for which resistance is associated with the P. falciparum transporter ABCI3Petar P S Calic, Trent D Ashton, Mahta Mansouri, et al.
Chemmedchem|August 30, 2024
Lactam Truncation Yields a Dihydroquinazolinone Scaffold with Potent Antimalarial Activity that Targets PfATP4Trent D Ashton, Petar P S Calic, Madeline G Dans, et al.
ACS Infectious Diseases|November 1, 2016
Biochemical and Structural Characterization of Selective Allosteric Inhibitors of the Plasmodium falciparum Drug Target, Prolyl-tRNA-synthetaseStephen Nakazawa Hewitt, David M Dranow, Benjamin G Horst, et al.
Journal of Medicinal Chemistry|November 8, 2021
An Open Drug Discovery Competition: Experimental Validation of Predictive Models in a Series of Novel AntimalarialsEdwin G Tse, Laksh Aithani, Mark Anderson, et al.
Journal of Medicinal Chemistry|August 12, 2024
Property and Activity Refinement of Dihydroquinazolinone-3-carboxamides as Orally Efficacious Antimalarials that Target PfATP4Trent D Ashton, Petar P S Calic, Madeline G Dans, et al.
Nature Communications|September 30, 2022
A G358S mutation in the Plasmodium falciparum Na<sup>+</sup> pump PfATP4 confers clinically-relevant resistance to cipargaminDeyun Qiu, Jinxin V Pei, James E O Rosling, et al.
Journal of Medicinal Chemistry|April 14, 2025
Optimization and Characterization of N-Acetamide Indoles as Antimalarials That Target PfATP4Jon Kyle Awalt, Zi Kang Ooi, Trent D Ashton, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 3, 2014
(+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of PlasmodiumMaría Belén Jiménez-Díaz, Daniel Ebert, Yandira Salinas, et al.
Pageof 13